Immunomodulating properties of the antibiotic novobiocin in human monocytes.
Standard
Immunomodulating properties of the antibiotic novobiocin in human monocytes. / Lührmann, A; Thölke, J; Behn, I; Schumann, J; Tiegs, Gisa; Hauschildt, S.
In: ANTIMICROB AGENTS CH, Vol. 42, No. 8, 8, 1998, p. 1911-1916.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Immunomodulating properties of the antibiotic novobiocin in human monocytes.
AU - Lührmann, A
AU - Thölke, J
AU - Behn, I
AU - Schumann, J
AU - Tiegs, Gisa
AU - Hauschildt, S
PY - 1998
Y1 - 1998
N2 - We show that the coumeromycin antibiotic novobiocin, a potent inhibitor of ADP ribosylation, prevents lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF-alpha), interleukin-1 (IL-1), IL-6, and IL-10 secretion in human peripheral blood mononuclear cells. It shares these cytokine-suppressing properties with other inhibitors of ADP ribosylation. We found that novobiocin prevents TNF-alpha production by inhibiting translation of the TNF-alpha mRNA. Elevated TNF-alpha levels in mice treated with D-galactosamine (GalN)-LPS or GalN-TNF were not reduced by novobiocin; however, the drug exhibited hepatoprotective properties. Novobiocin causes downregulation of the surface molecules on monocytes, among which CD14 was the most affected. The diminished expression of surface molecules was not observed on T and B lymphocytes. Similar to other inhibitors of ADP ribosylation, novobiocin prevents LPS-induced phosphate labelling of gamma-actins.
AB - We show that the coumeromycin antibiotic novobiocin, a potent inhibitor of ADP ribosylation, prevents lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF-alpha), interleukin-1 (IL-1), IL-6, and IL-10 secretion in human peripheral blood mononuclear cells. It shares these cytokine-suppressing properties with other inhibitors of ADP ribosylation. We found that novobiocin prevents TNF-alpha production by inhibiting translation of the TNF-alpha mRNA. Elevated TNF-alpha levels in mice treated with D-galactosamine (GalN)-LPS or GalN-TNF were not reduced by novobiocin; however, the drug exhibited hepatoprotective properties. Novobiocin causes downregulation of the surface molecules on monocytes, among which CD14 was the most affected. The diminished expression of surface molecules was not observed on T and B lymphocytes. Similar to other inhibitors of ADP ribosylation, novobiocin prevents LPS-induced phosphate labelling of gamma-actins.
KW - Animals
KW - Humans
KW - Mice
KW - Mice, Inbred BALB C
KW - Phosphorylation
KW - RNA, Messenger/analysis
KW - Anti-Bacterial Agents/pharmacology
KW - Cytokines/biosynthesis
KW - Lipopolysaccharides/pharmacology
KW - Antigens, CD14/analysis
KW - Monocytes/drug effects/immunology
KW - Novobiocin/pharmacology
KW - Protein Biosynthesis
KW - Tumor Necrosis Factor-alpha/genetics
KW - Animals
KW - Humans
KW - Mice
KW - Mice, Inbred BALB C
KW - Phosphorylation
KW - RNA, Messenger/analysis
KW - Anti-Bacterial Agents/pharmacology
KW - Cytokines/biosynthesis
KW - Lipopolysaccharides/pharmacology
KW - Antigens, CD14/analysis
KW - Monocytes/drug effects/immunology
KW - Novobiocin/pharmacology
KW - Protein Biosynthesis
KW - Tumor Necrosis Factor-alpha/genetics
M3 - SCORING: Journal article
VL - 42
SP - 1911
EP - 1916
JO - ANTIMICROB AGENTS CH
JF - ANTIMICROB AGENTS CH
SN - 0066-4804
IS - 8
M1 - 8
ER -
